Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Sell
25
NIKA Quote, Financials, Valuation and Earnings
Last price:
$0.28
Seasonality move
:
0%
Day range:
$0.27 - $0.28
52-week range:
$0.19 - $1.00
Dividend yield:
0%
P/E ratio:
47,385.00x
P/S ratio:
--
P/B ratio:
--
Volume:
10.4K
Avg. volume:
1.7K
1-year change:
-44.8%
Market cap:
$291.2M
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NIKA
Nika Pharmaceuticals, Inc.
|
-- | -- | -- | -- | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.20 | -- | -26.67% | $7.00 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NIKA
Nika Pharmaceuticals, Inc.
|
$0.28 | -- | $291.2M | 47,385.00x | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3.16 | $0.85 | $398.2M | 5.31x | $0.80 | 0% | 6.14x |
|
NNVC
NanoViricides, Inc.
|
$1.29 | $7.00 | $23.2M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.83 | $2.00 | $679.7K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.21 | $7.00 | $7M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NIKA
Nika Pharmaceuticals, Inc.
|
-- | -0.545 | -- | 0.33x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NIKA
Nika Pharmaceuticals, Inc.
|
-- | -$13K | -- | -- | -35128.21% | -$12.9K |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Nika Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns NIKA or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -35128.21% compared to Nika Pharmaceuticals, Inc.'s net margin of -255.85%. Nika Pharmaceuticals, Inc.'s return on equity of -- beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital NIKANika Pharmaceuticals, Inc.-- -- -$246.6K NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About NIKA or NBY?
Nika Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -73.1%. Given that NovaBay Pharmaceuticals, Inc. has higher upside potential than Nika Pharmaceuticals, Inc., analysts believe NovaBay Pharmaceuticals, Inc. is more attractive than Nika Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NIKANika Pharmaceuticals, Inc.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is NIKA or NBY More Risky?
Nika Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock NIKA or NBY?
Nika Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Nika Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NIKA or NBY?
Nika Pharmaceuticals, Inc. quarterly revenues are $160, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Nika Pharmaceuticals, Inc.'s net income of -$13K is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Nika Pharmaceuticals, Inc.'s price-to-earnings ratio is 47,385.00x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 5.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nika Pharmaceuticals, Inc. is -- versus 6.14x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NIKANika Pharmaceuticals, Inc.-- 47,385.00x $160 -$13K NBYNovaBay Pharmaceuticals, Inc.6.14x 5.31x $521K -$1.3M
-
Which has Higher Returns NIKA or NNVC?
NanoViricides, Inc. has a net margin of -35128.21% compared to Nika Pharmaceuticals, Inc.'s net margin of --. Nika Pharmaceuticals, Inc.'s return on equity of -- beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital NIKANika Pharmaceuticals, Inc.-- -- -$246.6K NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About NIKA or NNVC?
Nika Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand NanoViricides, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 442.64%. Given that NanoViricides, Inc. has higher upside potential than Nika Pharmaceuticals, Inc., analysts believe NanoViricides, Inc. is more attractive than Nika Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NIKANika Pharmaceuticals, Inc.0 0 0 NNVCNanoViricides, Inc.0 0 0 -
Is NIKA or NNVC More Risky?
Nika Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock NIKA or NNVC?
Nika Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nika Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NIKA or NNVC?
Nika Pharmaceuticals, Inc. quarterly revenues are $160, which are larger than NanoViricides, Inc. quarterly revenues of --. Nika Pharmaceuticals, Inc.'s net income of -$13K is higher than NanoViricides, Inc.'s net income of -$1.8M. Notably, Nika Pharmaceuticals, Inc.'s price-to-earnings ratio is 47,385.00x while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nika Pharmaceuticals, Inc. is -- versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NIKANika Pharmaceuticals, Inc.-- 47,385.00x $160 -$13K NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns NIKA or OGEN?
Oragenics, Inc. has a net margin of -35128.21% compared to Nika Pharmaceuticals, Inc.'s net margin of --. Nika Pharmaceuticals, Inc.'s return on equity of -- beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital NIKANika Pharmaceuticals, Inc.-- -- -$246.6K OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About NIKA or OGEN?
Nika Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 142.13%. Given that Oragenics, Inc. has higher upside potential than Nika Pharmaceuticals, Inc., analysts believe Oragenics, Inc. is more attractive than Nika Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NIKANika Pharmaceuticals, Inc.0 0 0 OGENOragenics, Inc.1 0 0 -
Is NIKA or OGEN More Risky?
Nika Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock NIKA or OGEN?
Nika Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nika Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NIKA or OGEN?
Nika Pharmaceuticals, Inc. quarterly revenues are $160, which are larger than Oragenics, Inc. quarterly revenues of --. Nika Pharmaceuticals, Inc.'s net income of -$13K is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Nika Pharmaceuticals, Inc.'s price-to-earnings ratio is 47,385.00x while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nika Pharmaceuticals, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NIKANika Pharmaceuticals, Inc.-- 47,385.00x $160 -$13K OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns NIKA or PTN?
Palatin Technologies has a net margin of -35128.21% compared to Nika Pharmaceuticals, Inc.'s net margin of --. Nika Pharmaceuticals, Inc.'s return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NIKANika Pharmaceuticals, Inc.-- -- -$246.6K PTNPalatin Technologies-- -- -- -
What do Analysts Say About NIKA or PTN?
Nika Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Nika Pharmaceuticals, Inc., analysts believe Palatin Technologies is more attractive than Nika Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NIKANika Pharmaceuticals, Inc.0 0 0 PTNPalatin Technologies0 0 0 -
Is NIKA or PTN More Risky?
Nika Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock NIKA or PTN?
Nika Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nika Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NIKA or PTN?
Nika Pharmaceuticals, Inc. quarterly revenues are $160, which are larger than Palatin Technologies quarterly revenues of --. Nika Pharmaceuticals, Inc.'s net income of -$13K is higher than Palatin Technologies's net income of --. Notably, Nika Pharmaceuticals, Inc.'s price-to-earnings ratio is 47,385.00x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nika Pharmaceuticals, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NIKANika Pharmaceuticals, Inc.-- 47,385.00x $160 -$13K PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns NIKA or TOVX?
Theriva Biologics, Inc. has a net margin of -35128.21% compared to Nika Pharmaceuticals, Inc.'s net margin of --. Nika Pharmaceuticals, Inc.'s return on equity of -- beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital NIKANika Pharmaceuticals, Inc.-- -- -$246.6K TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About NIKA or TOVX?
Nika Pharmaceuticals, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3284.91%. Given that Theriva Biologics, Inc. has higher upside potential than Nika Pharmaceuticals, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Nika Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NIKANika Pharmaceuticals, Inc.0 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is NIKA or TOVX More Risky?
Nika Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock NIKA or TOVX?
Nika Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nika Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NIKA or TOVX?
Nika Pharmaceuticals, Inc. quarterly revenues are $160, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Nika Pharmaceuticals, Inc.'s net income of -$13K is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Nika Pharmaceuticals, Inc.'s price-to-earnings ratio is 47,385.00x while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nika Pharmaceuticals, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NIKANika Pharmaceuticals, Inc.-- 47,385.00x $160 -$13K TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
39
SMX alert for Dec 17
SMX (Security Matters) Plc [SMX] is up 10.73% over the past day.
Sell
45
ZBIO alert for Dec 17
Zenas BioPharma, Inc. [ZBIO] is down 2.93% over the past day.
Buy
53
BE alert for Dec 17
Bloom Energy Corp. [BE] is down 12.34% over the past day.
